Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 445-455

  Figurski, Michal J ^a   Nawrocki, Artur ^a   Pescovitz, Mark D ^b   Bouw, Rene ^c   Shaw, Leslie M ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cyclosporine; Limited sampling strategy; Mycophenolic acid; Pharmacokinetics; Sirolimus

Indexed keywords

CYCLOSPORIN; DACLIZUMAB; GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BOOTSTRAPPING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; KIDNEY GRAFT REJECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL MODEL; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY; BLOOD; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVER; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; REPRODUCIBILITY;

ADULT; AGED; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SIROLIMUS; YOUNG ADULT;

EID: 58149106229     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318180c986     Document Type: Article

References (26)

1. Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transpl. 2005;5:874-886.
2. Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999;45:419-422.
3. Shipkova M, Armstrong VW, Weber L, et al. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit. 2002;24:390-399.
4. Mourad M, Malaise J, Eddour DCh, et al. Correlations of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47:88-94.
5. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;25:305-315.
6. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-1083.
7. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharm Ther. 1998;64:672-683.
8. Cattaneo D, Merlini S, Zenoni Set al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5:2937-2944.
9. Baraldo M, Isola M, Feruglio MT, et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. Transpl Proc. 2005;37:2240-2243.
10. van Hest RM, Mathot RA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients. Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit. 2004;26:620-625.
11. LeGuellec Ch, Buechler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharm. 2002;57:805-811.
12. Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transpl Proc. 2001;33: 1052-1053.
13. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002; 48:1497-1504.
14. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2 and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int. 2004;17:120-125.
15. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000;22:169-173.
16. Pescovitz MD, Guash A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transpl. 2003;3: 1581-1586.
17. Pescovitz MD, Flavio V, Hart M, et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol. 2007;64: 758-771.
18. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
19. Picard N, Premaud A, Rousseau A, et al. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol. 2006;62: 477-484.
20. Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
21. Hesselink DA, Van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
22. Kuypers DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003;43:866-880.
23. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871-880.
24. Prémaud A, Le Meur Y, Debord J, et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27: 354-361.
25. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503.
26. Le Guellec C, Bourgoin H, Büchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet. 2004;43:253-266.